Zolpidem and Possible Side Effects on Brain Circulation: A Case Report and Review of Literature
The brain is one of the most sensitive organs to hypoxia and the most vulnerable to ischemia and vascular events. Zolpidem, as a GABA-A receptor agonist, has an inhibiting effect on the central nervous system. In this study, the possible side effects of zolpidem on brain perfusion were reported in a patient with zolpidem addiction. Moreover, the correlated literature has been reviewed. The patient was a 33-year-old man who was referred with a complaint of cognitive impairment, gait disturbance, confusion, and seizure. The patient reported taking the daily dose of 270 mg of zolpidem. He developed acute dystonia, rigidity, and bradykinesia during treatment with haloperidol in the psychiatric ward. Brain MRI and EEG were requested due to the prolongation of cognitive impairment and parkinsonism symptoms. The Neurologist utilized Brain MRA to determine the source of microvascular lesions found in the brain MRI. Unexpectedly, a reduction in Anterior Cerebral Artery (ACA) perfusion was detected after a comprehensive evaluation by Brain MRA. In addition, impairment of several cognitive domains was observed in the follow-up visit. Zolpidem could reduce cerebral perfusion in various vascular territories. It seems that in patients who take zolpidem with higher than therapeutic doses, vascular complications and a decreased cerebral perfusion have occurred, resulting in more neurological complications, including cognitive disorders and vascular events. A holistic investigation of the patient with zolpidem abuse and neurological symptoms would be recommended to determine the probable vascular complication of zolpidem.
2. Najjar M. Zolpidem and amnestic sleep-related eating disorder. J Clin Sleep Med. 2007;3(6):637-8.
3. Hosseini E, Khatamsaz S, Goodarzi A. The effects of zolpidem medicine on thyroid plasmic hormones of T3, T4 and TSH in male mature rats. Pars of Jahrom University of Medical Sciences. 2011;9(1):1-6.
4. Zhang L, Blomgren K, Kuhn HG, Cooper-Kuhn CM. Effects of postnatal thyroid hormone deficiency on neurogenesis in the juvenile and adult rat. Neurobiol Dis. 2009;34(2):366-74.
5. Clauss RP, Güldenpfennig WM, Nel HW, Sathekge MM, Venkannagari RR. Extraordinary arousal from semi-comatose state on zolpidem. A case report. S Afr Med J. 2000;90(1):68-72.
6. Clauss RP, Dormehl IC, Oliver DW, Nel WH, Kilian E, Louw WK. Measurement of cerebral perfusion after zolpidem administration in the baboon model. Arzneimittelforschung. 2001;51(8):619-22.
7. Dormehl I, Redelinghuys F, Hugo N, Oliver D, Pilloy W. The baboon model under anesthesia for in vivo cerebral blood flow studies using single photon emission computed tomographic (SPECT) techniques. J Med Primatol. 1992;21(5):270-4.
8. Arbilla S, Depoortere H, George P, Langer SZ. Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats. Naunyn Schmiedebergs Arch Pharmacol. 1985;330(3):248-51.
9. Hoque R, Chesson AL. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med. 2009;5(5):471-6.
10. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59(4):865-89.
11. Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central Nervous System Side Effects Associated with Zolpidem Treatment. Clinical Neuropharmacology. 2000;23(1).
12. Wong CK, Marshall NS, Grunstein RR, et al. Spontaneous Adverse Event Reports Associated with Zolpidem in the United States 2003-2012. J Clin Sleep Med. 2017;13(2):223-34.
13. Bomalaski MN, Claflin ES, Townsend W, Peterson MD. Zolpidem for the Treatment of Neurologic Disorders: A Systematic Review. JAMA Neurol. 2017;74(9):1130-9.
14. Anonymous. Zolpidem overdose: Command hallucinations with self-stabbing: case report. Reactions Weekly. 2010(1297):50.
15. Sabe M, Kashef H, Gironi C, Sentissi O. Zolpidem stimulant effect: Induced mania case report and systematic review of cases. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94:109643.
16. Kinnan S, Petty F, Wilson DR. Zolpidem-induced mania in a patient with schizoaffective disorder. Psychosomatics. 2011;52(5):493-4.
17. Clauss RP, Nel WH. Effect of zolpidem on brain injury and diaschisis as detected by 99mTc HMPAO brain SPECT in humans. Arzneimittelforschung. 2004;54(10):641-6.
18. Sutton JA, Clauss RP. A review of the evidence of zolpidem efficacy in neurological disability after brain damage due to stroke, trauma and hypoxia: A justification of further clinical trials. Brain Inj. 2017;31(8):1019-27.
19. Khalili H, Rakhsha A, Ghaedian T, Niakan A, Masoudi N. Application of Brain Perfusion SPECT in the Evaluation of Response to Zolpidem Therapy in Consciousness Disorder Due to Traumatic Brain Injury. Indian J Nucl Med. 2020;35(4):315-20.
20. Mattila MJ, Vanakoski J, Kalska H, Seppälä T. Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav. 1998;59(4):917-23.
21. Licata SC, Lowen SB, Trksak GH, Maclean RR, Lukas SE. Zolpidem reduces the blood oxygen level-dependent signal during visual system stimulation. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1645-52.
|Issue||Vol 10, No 4 (Autumn 2022)|
|Zolpidem Brain Perfusion Complication|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|